Home
About Us
AdAlta at a glance
Board
Management Team
World Class Scientific Advisors
Technology
i-bodies
The i-body platform
Scientific Publications
Pipeline
The Growing AdAlta Pipeline
Fibrosis
CAR-T cancer therapeutics
Investors
Annual and Financial Reports
Presentations
Analyst Reports
ASX Announcements
News & Media
Corporate Governance
Contact Us
..Author:
Ben Eversfield
Collaboration Agreement with XL-Protein
November 7, 2016
Quarterly Review and Appendix 4C
October 27, 2016
Change of Director’s Interest Notice
October 23, 2016
Appendix 3B
October 23, 2016
AdAlta to present at forthcoming industry conferences
October 18, 2016
Update on Orphan Drug Designation
October 14, 2016
Notice of Annual General Meeting 2016
October 4, 2016
Change of Director’s Interest Notice
September 27, 2016
Change of Director’s Interest Notice
September 27, 2016
Appendix 3B
September 27, 2016
Posts navigation
Older posts
Newer posts
Archives
2016 News
Initial Director’s Interest Notice
AdAlta Extends Board with Appointment of US-Based Non Executive Director
Director Appointment
Results of AdAlta AGM 2016
AGM Presentation
2015 News
AdAlta and The University of Melbourne to develop i-bodies for the treatment of various eye diseases
Japanese patent granted for AdAlta i-body technology
AdAlta appoints Dr Paul MacLeman Chairman
AdAlta expands its scientific advisory team
2014 News
AdAlta expands its scientific advisory team
Lonza and AdAlta Announce a Strain Development Contract for Novel Biologic Therapeutics
2013 News
AdAlta collaborates with Crossbeta to find i-body for Alzheimer’s disease
AdAlta awarded voucher to explore benefits of technologies with Ferring Research Institute
2012 News
AdAlta and Baker IDI sign agreement to identify i-bodies to anti-thrombotic target
AdAlta and Roche sign agreement to evaluate shark antibody technology
2011 News
US patent granted for AdAlta i-body technology
AdAlta receives VC investment from Perth-based Yuuwa Capital